Personally I would not want to be a buy up here as were hitting major resistance and a choppy trading zone. The monthly chart looks exhausted and ready to take a break. We all know biotechs are crazy, they can run & run and run then on the flip of a dime they crash much harder & faster than they came up.
After having this non-stop run over the past 3 year, I would not be surprised to see a pull-back in the near future even though they had a great 10Q & have plenty of cash from the Janssen deal. Here are some important notes from the 10Q
sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-10k_20190930.htm
We expect that the market price of our Common Stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all.
We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.
We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development and discovery efforts.
Janssen, and the premium JJDC paid on the Company’s common stock during the period.
With this being said I am looking at 6/19/20 $50 Puts
& for more near-term i'm looking at 3/20/20 $50 puts
GLTA
免责声明
这些信息和出版物并非旨在提供,也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
免责声明
这些信息和出版物并非旨在提供,也不构成TradingView提供或认可的任何形式的财务、投资、交易或其他类型的建议或推荐。请阅读使用条款了解更多信息。
